Palatin Technologies Inc (PTN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Palatin Technologies Inc (PTN) has a cash flow conversion efficiency ratio of 0.838x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.35 Million) by net assets ($-6.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Palatin Technologies Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Palatin Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PTN total debt and obligations for a breakdown of total debt and financial obligations.
Palatin Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palatin Technologies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Infinitum Copper Corp
V:INFI
|
-7.611x |
|
MOBILUM TECHNOLOGIES INC.
F:C0B
|
N/A |
|
ASA International Group PLC
LSE:ASAI
|
0.186x |
|
Permaju Industries Bhd
KLSE:7080
|
-0.004x |
|
CLS Holdings plc
LSE:CLI
|
0.008x |
|
Vertu Motors Plc
LSE:VTU
|
0.044x |
|
HELIUM ONE GLOBAL LTD.
F:9K3
|
N/A |
|
ZW Data Action Technologies Inc
NASDAQ:CNET
|
-0.143x |
Annual Cash Flow Conversion Efficiency for Palatin Technologies Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of Palatin Technologies Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Palatin Technologies Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $-111.50K | $-31.46 Million | 282.173x | +233.12% |
| 2023-06-30 | $134.07K | $-28.42 Million | -211.967x | -11423.83% |
| 2022-06-30 | $16.27 Million | $-29.92 Million | -1.839x | -303.25% |
| 2021-06-30 | $49.65 Million | $-22.65 Million | -0.456x | -188.49% |
| 2020-06-30 | $80.17 Million | $41.33 Million | 0.515x | +337.94% |
| 2019-06-30 | $100.55 Million | $-21.78 Million | -0.217x | -443.00% |
| 2018-06-30 | $26.96 Million | $1.70 Million | 0.063x | +102.53% |
| 2017-06-30 | $-5.16 Million | $12.88 Million | -2.494x | -192.61% |
| 2016-06-30 | $-17.59 Million | $-47.36 Million | 2.693x | +346.07% |
| 2015-06-30 | $12.20 Million | $-13.36 Million | -1.095x | +12.23% |
| 2014-06-30 | $9.79 Million | $-12.21 Million | -1.247x | -109.95% |
| 2013-06-30 | $22.98 Million | $-13.65 Million | -0.594x | +92.98% |
| 2012-06-30 | $1.83 Million | $-15.49 Million | -8.459x | -1295.05% |
| 2011-06-30 | $18.19 Million | $-11.03 Million | -0.606x | +1.39% |
| 2010-06-30 | $9.32 Million | $-5.73 Million | -0.615x | +62.57% |
| 2009-06-30 | $3.31 Million | $-5.44 Million | -1.643x | +47.69% |
| 2008-06-30 | $6.55 Million | $-20.58 Million | -3.141x | -163.94% |
| 2007-06-30 | $18.53 Million | $-22.05 Million | -1.190x | +7.13% |
| 2006-06-30 | $18.30 Million | $-23.45 Million | -1.281x | -133.44% |
| 2005-06-30 | $9.23 Million | $-5.06 Million | -0.549x | +55.18% |
| 2004-06-30 | $19.39 Million | $-23.74 Million | -1.225x | -14.86% |
| 2003-06-30 | $18.66 Million | $-19.89 Million | -1.066x | +29.55% |
| 2002-06-30 | $8.69 Million | $-13.15 Million | -1.513x | -114.75% |
| 2001-06-30 | $11.92 Million | $-8.40 Million | -0.705x | +43.02% |
| 2000-06-30 | $6.91 Million | $-8.54 Million | -1.237x | +96.43% |
| 1999-06-30 | $300.00K | $-10.40 Million | -34.667x | -1492.79% |
| 1998-06-30 | $3.40 Million | $-7.40 Million | -2.176x | -420.23% |
| 1997-06-30 | $9.80 Million | $-4.10 Million | -0.418x | +56.18% |
| 1996-06-30 | $2.84 Million | $-2.71 Million | -0.955x | -- |
About Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is… Read more